# Testing vitamin A to prevent pancreas inflammation in children with leukemia during treatment

Submission date	<b>Recruitment status</b> Recruiting	[X] Prospectively registered			
09/10/2024		[X] Protocol			
Registration date	Overall study status Ongoing  Condition category Cancer	Statistical analysis plan			
19/10/2024		☐ Results			
Last Edited		<ul><li>Individual participant data</li><li>Record updated in last year</li></ul>			
18/10/2024					

## Plain English summary of protocol

Background and study aims

Asparaginase (ASNase) is one of the preferred drugs for the current treatment of acute lymphoblastic leukemia (ALL). Since the drug introduced into the treatment of pediatric ALL in the 1960s, the survival rate for pediatric ALL has gradually increased from 50% to nearly 90%. However, during the course of treatment with ASNase, approximately 2%-10% of patients develop asparaginase-associated pancreatitis (AAP). Once AAP occurs, due to the high risk of reuse, the drug is typically discontinued in clinical practice, leading to poor outcomes in children with ALL. Due to the unclear pathogenesis, current clinical methods for preventing AAP are limited. Although low-fat, low-oil dietary strategies have been implemented in clinical practice for children undergoing ASNase treatment, they have not proven to be effective in preventing AAP. Recently, the researchers suggest that ASNase reduces retinoid levels in patients, and intake of vitamin A may reduce the risk of pancreatitis in leukemia patients treated with ASNase. These findings provide an important reference for the clinical prevention of AAP, but since the data are based on retrospective studies in European and American children and adult ALL populations, the strength of the evidence needs to be further reinforced. Therefore, this study aims to design a prospective study to evaluate the correlation between vitamin A levels and AAP incidence, thereby providing data and theoretical support for the clinical prevention of AAP.

# Who can participate?

Children with age between one month and 18 years old and diagnosed with ALL.

# What does the study involve?

Participants are asked to join this study while they are staying in the hospital. Participants who meet the inclusion and exclusion criteria will receive vitamin A. After enrollment, the patients were observed for 60 days. The study will lasts two years in total.

# What are the possible benefits and risks of participating?

There will be immediate direct benefit to those taking part, or not. But there should be benefit to the patients in the future because the results of the study are likely to reduce the incidence of AAP. The main risk of giving vitamin A is that bone and joint pain, swelling, itchy skin, chapped

lips, fever, headache, vomiting, constipation, diarrhea and nausea, which can be resumed when the drug is stopped.

Where is the study run from?

The PREVAIL study is being run by the Children's Hospital of Soochow University in China.

When is the study starting and how long is it expected to run for? September 2024 to October 2026

Who is funding the study? Children's Hospital of Soochow University (China)

Who is the main contact?

- 1. Prof. Shaoyan Hu, hsy139@126.com
- 2. Prof. Zhenjiang, 18913510429@163.com

# Contact information

#### Type(s)

Public, Scientific, Principal investigator

#### Contact name

Prof Shaoyan Hu

#### **ORCID ID**

https://orcid.org/0000-0002-3386-6957

#### Contact details

No.92 Zhongnan Street, SIP Suzhou China 215000 +86 13771870462 hsy139@126.com

#### Type(s)

Public, Scientific, Principal investigator

#### Contact name

Prof Zhenjiang Bai

#### **ORCID ID**

https://orcid.org/0000-0002-9404-7058

#### Contact details

No.92 Zhongnan street,SIP Suzhou China 215000 +86 18913510429 18913510429@163.com

# Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

## ClinicalTrials.gov (NCT)

Nil known

#### Protocol serial number

Nil known

# Study information

#### Scientific Title

The Supplementation of Vitamin A for the Prevention of Asparaginase-Associated Pancreatitis in Children With Acute Lymphoblastic Leukemia: A Prospective Single-arm Clinical Trial

#### **Acronym**

**PREVAIL** 

#### Study objectives

Vitamin A can reduce the incidence of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia

# Ethics approval required

Ethics approval required

# Ethics approval(s)

approved 24/09/2024, Children's Hospital of Soochow University (No.92 zhongnan street, SIP, Suzhou, 215000, China; +86 512-80693506; sdfetyyec@163.com), ref: 2024016

# Study design

Single center interventional single-arm clinical trial

# Primary study design

Interventional

# Study type(s)

Prevention, Efficacy

# Health condition(s) or problem(s) studied

Prevention of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia

#### **Interventions**

After completing screening measurements and acquiring written informed consent, children participating in this study will receive 3600 unit vitamin A orally per day for 30 days. The dosage will be adjusted based on the blood level of vitamin A but will not exceed 8000U/L. A historical retrospective cohort will be used as the control group.

#### Intervention Type

Supplement

#### Primary outcome(s)

The incidence of asparaginase-associated pancreatitis within 60 days after enrollment measured using patient records

## Key secondary outcome(s))

- 1. Incidence of elevated blood amylase within 30 days of enrollment: blood amylase levels are routinely monitored twice weekly for 30 days after the use of asparaginase. Any value above the normal range at any monitoring point is defined as elevated.
- 2. Length of Hospital Stay: the duration from enrollment to discharge measured using patient records.
- 3. 28-Day Mortality after enrollment measured using patient records
- 4. The vitamin A levels monitoring: the plasma vitamin A levels is monitored at enrollment, and 1, 2, 3, 4 and 6 weeks after enrollment.
- 5. Duration of Enteral Nutrition Interruption within 60 days of enrollment measured using patient records.
- 6. Prothrombin time, International Normalized Ratio, Activated partial thromboplastin time, fibrinogen, AT-III, albumin levels within 30 days after enrollment.
- 7. Cumulative use of plasma within 30 days after enrollment.

#### Completion date

31/10/2026

# Eligibility

#### Key inclusion criteria

- 1. One month< age ≤18 years
- 2. Diagnosis with acute lymphoblastic leukemia, which was confirmed by cell morphology, immunology, cytogenetics and molecular biology

# Participant type(s)

Patient

# Healthy volunteers allowed

No

# Age group

Child

# Lower age limit

1 months

# Upper age limit

18 years

#### Sex

All

#### Key exclusion criteria

- 1. Previous history of pancreatitis or other conditions that may lead to pancreatitis (such as hyperlipidemia, hypercholesterolemia, and cholelithiasis)
- 2. Treatment course delays of more than two weeks due to financial issues
- 3. Exclusion of cases where acute pancreatitis occurs without the use of PEG-asparaginase (PEG-ASP)
- 4. The patient switching from PEG-ASP to L-ASP or Erwinia-ASP treatment due to adverse reactions other than AAP
- 5. Expected hospital stay of less than 2 days
- 6. Use of vitamin A supplements prior to enrollment within 1 month

#### Date of first enrolment

01/11/2024

#### Date of final enrolment

31/10/2026

# Locations

#### Countries of recruitment

China

## Study participating centre Children's Hospital of Soochow University

No.92 Zhongnan street, SIP Suzhou China 215000

# Sponsor information

#### Organisation

Children's Hospital of Soochow University

# Funder(s)

# Funder type

Other

#### **Funder Name**

Investigator initiated and funded

# **Results and Publications**

# Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the results publication.

# IPD sharing plan summary

Published as a supplement to the results publication

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Protocol file			18/10/2024	No	No